Assessment of Small Dense Low-Density Lipoprotein and Apolipoprotein B/Apolipoprotein A-I Ratio to Predict the Peripheral Arterial Disease in Patients with Hypertension

Kurniawan Prihutomo, MID. Pramudianti, Amiroh Kurniati


Small Dense Low-Density Lipoprotein (sdLDL) and the ApoB/ApoA-I ratio has greater atherogenic potential and is a better marker to predict atherosclerotic blood vessel disease. The purpose of this study was to determine the relationship between the sdLDL and ApoB/ApoA-I ratio to assess the prevalence risk of Peripheral Arterial Disease (PAD) in hypertensive patients. A cross-sectional observational analytic study was performed in 51 hypertension patients with age> 18 years old in Dr. Moewardi Hospital Surakarta from May until June 2018. Patients have measured ABI scores, BMI, blood pressure, lipid profile, ApoB, and ApoA levels. Data were statistically analyzed was using bivariate analysis and multivariate analysis. P-value <0.05 was statistically significant. The prevalence of PAD was 54.90%. Bivariate analysis of age variables (PR: 3.15; 95%Cl: 1.128-8.811; p=0.005), sdLDL (PR: 2; 95%Cl: 0.997-4.013; p=0.03), the ratio of ApoB/ApoA-I (PR: 5.786; 95%Cl: 0.899-37.224; p=0.007), and smoking (PR: 1.896; 95%Cl: 1.210-2.971; p=0.015) was significantly related with PAD. After adjustment of age, smoking, and dyslipidemia variables using multivariate logistic regression analysis, PAD was still related with sdLDL (PR: 10.55; 95%CI: 1.80-61.73; p=0.009), age (PR: 11. 61; 95%CI: 1.83-61.73; p=0.009), and smoking (PR: 11.96; 95%CI: 1.71-83.81; p= 0.013). sdLDL and ApoB/ApoA-I ratio were related to PAD. However, sdLDL, age, and smoking are independent variables of PAD in hypertension patients.


sdLDL, ApoB/ApoA-I ratio, peripheral arterial disease, hypertension

Full Text:




Peach G., Griffin M., Jones K. G., Thomson M. M., Hincliffe R. J. 2012. Diagnosis and management of peripheral arterial disease. B M J. 345:1-8.

Sarkar T., Singh N. P. 2015. Epidemiology and genetic of hypertension. J Association Physicians Of India. 5:61-69.

Bennet P. C., Silverman S., Gill P. 2009. Hypertension and peripheral arterial disease. Journal Of Hypertension. 23: 213-215.

Olin J. W., Sealove B. 2010. Peripheral arterial disease : current insight into the disease and it diagnosis and management. Mayo Clin Proc. 7:672-692.

Hennion R. D., Siano K. A. 2013. Diagnosis and treatment of peripheral arterial disease. Am Fam Physician. 5:306-310.

Thiruvoipati T., Keilhorr C. E., Amstrong E. 2015. Peripheral artery disease in patient with diabetes : epidemiology, mechanism, and outcomes. Word J Diabetes. 7: 961-969.

Yang X. M., Sun K., Zang W., Wu H., Zhang H., Hui R. T. 2007. Prevalence of and risk factors for pad in the patient with hypertension among han chinese. J Vasc Sur. 46: 296-302.

Thendria T., Toruan I. L., Natalia D. 2014. Hubungan hipertensi dan penyakit arteri perifer berdasarkan nilai ankle brakial index. ISSN. 2338-1426

Gardner A. W., Alaupovic P., Parker D. E., Momtgomery P. S., Elponda O. L., Casanegra A. I. 2013. Influence of peripheral arterial disease and statin therapy on apolipoprotein profile. Int J Vasc Med. 33: 1-16.

Xu D., Zou L., Xing Y., Hou L., Wei Y., Li J., Zhang J., et al. 2013. Diagnostic value of ankle brachial index in peripheral arterial disease : a metaanalysis. Canadian J Cardio. 29: 492-498.

Steinberg D., Witztum J. L. 2011. Oxidaton specific epitopes are danger associated molecular pattern recognized by pattern recognation of innate immunnity. Circulation Resch. 2: 235-248.

Nikolic D., Katsiki N., Montalto G., Isenovic E. R., Mikhailidis D. P., Rizzo M. 2013. Lipoprotein subfraction in metabolic syndrome and obesity : clinical significance and therapeutic approaches. Nutrient. 3: 928-948.

Palazhy S., Kamath P., Vasudevan D. 2014. Estimation of small dense ldl particles using equations derived from routine lipid parameter as surrogate markers. Biochem Aral Biochem. 3: 1-5.

Kaneva A. M., Potolisyana N. N., Bojko E. R., Odland J. O. 2015. The Apoprotein B / apoprotein A-1 as a potensial marker of plasma atherogenicity. Disease Marker. 7: 1-7.

Ivanova E. A., Myasoedova V. A., Grechko A. V., Orekhov A. N. 2017. Small dense low density as biomarker for atherosclerotic disease. Oxidative Med Cell Longevity. 1: 1-10.

Kaneva A. M., Potolisyana N. N., Bojko E. R., Odland J. O. 2015. The Apoprotein B / apoprotein A-1 as a potensial marker of plasma atherogenicity. Disease Marker. 7: 1-7.

Desplantie O., Ramnathan K., Daskalopoulou S. S., Louisepilote M. E., Khan N. M. 2016. Can apoprotein apob nad ApoA-I ratio predict future cardiovascular risk pot acute coronary syndrome? a retrospective cohort study. J Clin Exp Cardiolog. 7: 5-17.

Shandu P. K., Musaad S. M. A., Remaley A. T. Bvehler H. W., Ranne A. 2016. Lipoprotein biomarker and risk of cardiovascular disease : a laboratory medicine best practice (LMBP) systemic review. J A L M. 2:214-229.

Lima L. M., Carvalho M. G., Sabino A. P., Mota A. P., Fernandes A. D., Osausa M. 2007. ApoB / ApoA-I ratio in central and peripheral arterial disease. Arg Bras Endocrinal Metab. 7: 1160-1165.

Jacomella V., Gerber P. A., Mosimann K., Husman M., Thalhammer C., Wilkinson I., Berneis K., et al. 2014. Small dense low density lipoprotein particles are associated with poop outcome after angiplasti in peripheral arterial disease. Plos One. 9: 1-5.

Li G., Wu H., Wu X., Cao Z., Tu Y., Ma Y., Wang W., et al. 2018. Small dense low density lipoprotein-cholesterol and cholesterol ratio to predict arterial stiffness progression in normotensive subjects over a 5 years period. Lipid in Health and Disease. 17:27.

Johansson L., Schmidt C. 2009. Increase ApoB/ApoA-I ratio is predictive of peripheral arterial disease in healthy 58 years old men during 8.9 years of follow up. Angiology. 60: 539-545.

Schmidt C., Fagerberg B., Wikstarnd J., Hulthe J. 2006. ApoB/ApoA–1 ratio is related to femoral artery plaques and is predictive for future cardiovascular events in healthy men. Atherosclerosis. 189 : 178–185.

Fowler B., Jamrozik K., Norman P., Allen Y. 2002. Prevalence of peripheral arterial disease: persistence of excess risk in former smoker. Aust N Z J Public Health. 26: 219-24.

Muir R. L. 2009. Peripheral arterial disease: pathophysiology, risk factors, disgnosis, treatment, and preventation. J Vasc Nurs. 27: 26-30.

Rizzo M., Pernice V., Berneis K. 2008. Atherogenic lipoprotein phenotype and LDL size and subclasses in patients with peripheral arterial disease. Atherosclerosis. 197:237-241.



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.